Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program
Open Access
- 24 November 2022
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (2) , 312-318
Abstract
Ibrutinib is a small molecule inhibitor of Bruton’s tyrosine kinase indicated for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). The Named Patient Program in Australia and New Zealand (ANZ NPP) provided access to ibrutinib treatment to 1126 R/R CLL/SLL and 330 R/R MCL patients, prior to Pharmaceutical Benefits Scheme listing. This study aimed to assess the duration of treatment for the ANZ NPP patients, as an indicator of efficacy and tolerability of ibrutinib in the real world. Based on the NPP data, ibrutinib provided a median of 47 months clinical benefit for participants with CLL/SLL and 14 months clinical benefit for those with MCL; outcomes that are consistent with the clinical trial results and further support the well-established efficacy and safety profile of ibrutinib in the real world.Keywords
Funding Information
- Janssen-Cilag Australia
This publication has 11 references indexed in Scilit:
- Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaBlood Advances, 2022
- Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-upHemaSphere, 2022
- PB1892 REAL WORLD TREATMENT PERSISTENCE OF NEW ZEALAND IBRUTINIB CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS IN A NAMED PATIENT PROGRAMHemaSphere, 2019
- Interpretation and Impact of Real-World Clinical Data for the Practicing ClinicianAdvances in Therapy, 2018
- Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2Haematologica, 2018
- Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLLLeukemia, 2017
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 studyThe Lancet, 2016
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2014
- Declaración de la Iniciativa STROBE (Strengthening the Reporting of Observational studies in Epidemiology): directrices para la comunicación de estudios observacionalesGaceta Sanitaria, 2008